Kazakhstan Health Minister Acknowledges Lobbying in Pharmaceutical Market

Kazakhstan's Health Minister Akmaral Alnazarova has admitted to the existence of lobbying within the pharmaceutical market, stating that industry participants are reluctant to lose high profits. The ministry has revised drug pricing and procurement rules, leading to reduced prices for medications from the unified distributor's list. New prices for the wholesale and retail segments were approved on July 17, 2025, with significant cost reductions observed.

Read the full article at Informburo →

Headline and summary written by daryo. The full report belongs to Informburo.